These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 38064969)
21. Epithelial to mesenchymal transition (EMT) in metaplastic breast cancer and phyllodes breast tumors. Akrida I; Mulita F; Plachouri KM; Benetatos N; Maroulis I; Papadaki H Med Oncol; 2023 Dec; 41(1):20. PubMed ID: 38104042 [TBL] [Abstract][Full Text] [Related]
22. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation. Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608 [TBL] [Abstract][Full Text] [Related]
23. The Potential for Natural Products to Overcome Cancer Drug Resistance by Modulation of Epithelial-Mesenchymal Transition. Dahmardeh Ghalehno A; Boustan A; Abdi H; Aganj Z; Mosaffa F; Jamialahmadi K Nutr Cancer; 2022; 74(8):2686-2712. PubMed ID: 34994266 [TBL] [Abstract][Full Text] [Related]
24. Tumor-associated macrophages and epithelial-mesenchymal transition in cancer: Nanotechnology comes into view. Vakili-Ghartavol R; Mombeiny R; Salmaninejad A; Sorkhabadi SMR; Faridi-Majidi R; Jaafari MR; Mirzaei H J Cell Physiol; 2018 Dec; 233(12):9223-9236. PubMed ID: 30078227 [TBL] [Abstract][Full Text] [Related]
25. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells. Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275 [TBL] [Abstract][Full Text] [Related]
26. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer. Glackin CA Enzymes; 2018; 44():83-101. PubMed ID: 30360816 [TBL] [Abstract][Full Text] [Related]
27. Tumor cell heterogeneity in Small Cell Lung Cancer (SCLC): phenotypical and functional differences associated with Epithelial-Mesenchymal Transition (EMT) and DNA methylation changes. Krohn A; Ahrens T; Yalcin A; Plönes T; Wehrle J; Taromi S; Wollner S; Follo M; Brabletz T; Mani SA; Claus R; Hackanson B; Burger M PLoS One; 2014; 9(6):e100249. PubMed ID: 24959847 [TBL] [Abstract][Full Text] [Related]
28. The role of CD29-ILK-Akt signaling-mediated epithelial-mesenchymal transition of liver epithelial cells and chemoresistance and radioresistance in hepatocellular carcinoma cells. Jiang X; Wang J; Zhang K; Tang S; Ren C; Chen Y Med Oncol; 2015 May; 32(5):141. PubMed ID: 25805567 [TBL] [Abstract][Full Text] [Related]
29. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. Creighton CJ; Chang JC; Rosen JM J Mammary Gland Biol Neoplasia; 2010 Jun; 15(2):253-60. PubMed ID: 20354771 [TBL] [Abstract][Full Text] [Related]
30. Distinct contributions of partial and full EMT to breast cancer malignancy. Lüönd F; Sugiyama N; Bill R; Bornes L; Hager C; Tang F; Santacroce N; Beisel C; Ivanek R; Bürglin T; Tiede S; van Rheenen J; Christofori G Dev Cell; 2021 Dec; 56(23):3203-3221.e11. PubMed ID: 34847378 [TBL] [Abstract][Full Text] [Related]
31. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Erin N; Grahovac J; Brozovic A; Efferth T Drug Resist Updat; 2020 Dec; 53():100715. PubMed ID: 32679188 [TBL] [Abstract][Full Text] [Related]
32. Pharmacological Targeting of Epithelial-to-Mesenchymal Transition in Colorectal Cancer. Zafari N; Velayati M; Nassiri M; Khazaei M; Hassanian SM; Ferns GA; Avan A Curr Pharm Des; 2022; 28(28):2298-2311. PubMed ID: 35909286 [TBL] [Abstract][Full Text] [Related]
33. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Byers LA; Diao L; Wang J; Saintigny P; Girard L; Peyton M; Shen L; Fan Y; Giri U; Tumula PK; Nilsson MB; Gudikote J; Tran H; Cardnell RJ; Bearss DJ; Warner SL; Foulks JM; Kanner SB; Gandhi V; Krett N; Rosen ST; Kim ES; Herbst RS; Blumenschein GR; Lee JJ; Lippman SM; Ang KK; Mills GB; Hong WK; Weinstein JN; Wistuba II; Coombes KR; Minna JD; Heymach JV Clin Cancer Res; 2013 Jan; 19(1):279-90. PubMed ID: 23091115 [TBL] [Abstract][Full Text] [Related]
34. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030 [TBL] [Abstract][Full Text] [Related]
35. Overcoming epithelial-mesenchymal transition-mediated drug resistance with monensin-based combined therapy in non-small cell lung cancer. Ochi K; Suzawa K; Tomida S; Shien K; Takano J; Miyauchi S; Takeda T; Miura A; Araki K; Nakata K; Yamamoto H; Okazaki M; Sugimoto S; Shien T; Yamane M; Azuma K; Okamoto Y; Toyooka S Biochem Biophys Res Commun; 2020 Aug; 529(3):760-765. PubMed ID: 32736704 [TBL] [Abstract][Full Text] [Related]
36. Epithelial Mesenchymal Transition in Aggressive Lung Cancers. Mittal V Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798 [TBL] [Abstract][Full Text] [Related]
37. Cisplatin resistance in gastric cancer cells is involved with GPR30-mediated epithelial-mesenchymal transition. Wang X; Xu Z; Sun J; Lv H; Wang Y; Ni Y; Chen S; Hu C; Wang L; Chen W; Cheng X J Cell Mol Med; 2020 Mar; 24(6):3625-3633. PubMed ID: 32052561 [TBL] [Abstract][Full Text] [Related]
38. The Impact of Epithelial-Mesenchymal Transition and Metformin on Pancreatic Cancer Chemoresistance: A Pathway towards Individualized Therapy. Gulla A; Andriusaityte U; Zdanys GT; Babonaite E; Strupas K; Kelly H Medicina (Kaunas); 2022 Mar; 58(4):. PubMed ID: 35454306 [TBL] [Abstract][Full Text] [Related]
39. Nanotechnology-empowered lung cancer therapy: From EMT role in cancer metastasis to application of nanoengineered structures for modulating growth and metastasis. Saleem HM; Ramaiah P; Gupta J; Jalil AT; Kadhim NA; Alsaikhan F; Ramírez-Coronel AA; Tayyib NA; Guo Q Environ Res; 2023 Sep; 232():115942. PubMed ID: 37080268 [TBL] [Abstract][Full Text] [Related]
40. The N-terminal polypeptide derived from viral macrophage inflammatory protein II reverses breast cancer epithelial-to-mesenchymal transition via a PDGFRα-dependent mechanism. Yang QL; Zhang LY; Wang HF; Li Y; Wang YY; Chen TT; Dai MF; Wu HH; Chen SL; Wang WR; Wu Q; Chen CJ; Zhou CZ Oncotarget; 2017 Jun; 8(23):37448-37463. PubMed ID: 28415580 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]